All Stories

  1. Identifying patients with acute total coronary occlusion in NSTEACS: finding the high-risk needle in the haystack
  2. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents
  3. Editor’s Choice-Medically managed patients with non–ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease
  4. Patient education after acute myocardial infarction
  5. Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?
  6. Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry
  7. Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: Insights from the RealiseAF Taiwanese cohort
  8. No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial
  9. Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early After Myocardial Infarction [STREAM] Study)
  10. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
  11. Beta-Blockers in Asymptomatic Coronary Artery Disease
  12. Impact of Living and Socioeconomic Characteristics on Cardiovascular Risk in Ischemic Stroke Patients
  13. Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction
  14. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
  15. Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry
  16. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial
  17. ANGIOPOIETIN-LIKE 4 SERUM LEVELS ON ADMISSION FOR ACUTE MYOCARDIAL INFARCTION ARE ASSOCIATED WITH NO-REFLOW ASSESSED BY MAGNETIC RESONANCE IMAGING
  18. CARDIOVASCULAR EVENT RATES IN PATIENTS WITH DIABETES: INSIGHTS FROM THE INTERNATIONAL REACH REGISTRY
  19. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
  20. BIOMARKERS FOR PREDICTION OF OUTCOMES IN REVASCULARIZED PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: A PLATO SUBSTUDY
  21. 0402: Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow
  22. Frequency of the Use of Low- Versus High-Dose Aspirin in Dual Antiplatelet Therapy After Percutaneous Coronary Intervention (from the Dual Antiplatelet Therapy Study)
  23. AORTIC INTRAMURAL HEMATOMA: PREDICTORS AND OUTCOMES OF PROGRESSION TO DISSECTION
  24. REDUCED DEATH, MYOCARDIAL INFARCTION, AND EARLY STENT THROMBOSIS WITH CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF BIVALIRUDIN: INSIGHTS FROM CHAMPION PHOENIX
  25. TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS
  26. BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS
  27. Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI
  28. Procedural Volume and Outcomes With Radial or Femoral Access for Coronary Angiography and Intervention
  29. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey
  30. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score
  31. Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
  32. Clinical Characteristics, Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey
  33. An Education Program for Risk Factor Management After an Acute Coronary Syndrome
  34. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry
  35. NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease
  36. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome
  37. Bivalirudin Started during Emergency Transport for Primary PCI
  38. Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): An international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myoc...
  39. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
  40. The Impact of Lost Therapeutic Benefit (LTB) in High‐Risk Hypertensive Patients: 2‐Year Follow‐Up Data from the Australian REACH Registry
  41. Aortic arch atheroma in transient ischemic attack patients
  42. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
  43. Predictors of Long‐term Adherence to Evidence‐based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry
  44. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
  45. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
  46. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of iva...
  47. Prognostic significance of presenting blood pressure in non–ST-segment elevation acute coronary syndrome in relation to prior history of hypertension
  48. TCT-10 Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization
  49. Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity‐Matched Study
  50. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes
  51. Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The RealiseAF Survey
  52. Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease
  53. Outcomes and Excess Costs among Patients with Cardiovascular Disease
  54. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non–ST-segment elevation acute coronary syndromes
  55. Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis
  56. Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice
  57. Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)
  58. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study
  59. Comparison of Hospital Mortality During ST-Segment Elevation Myocardial Infarction in the Era of Reperfusion Therapy in Women Versus Men and in Older Versus Younger Patients
  60. Cardiac diffusion‐weighted MR imaging in recent, subacute, and chronic myocardial infarction: A pilot study
  61. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
  62. Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?
  63. Radial versus femoral access, bleeding and ischemic events in patients with non–ST-segment elevation acute coronary syndrome managed with an invasive strategy
  64. PREDICTORS OF DUAL ANTIPLATELET THERAPY NON-ADHERENCE AFTER PCI: ONE-YEAR INSIGHTS FROM THE PARIS REGISTRY
  65. PREDICTORS OF LONG-TERM ADHERENCE TO EVIDENCE-BASED CARDIOVASCULAR DISEASE MEDICATIONS IN OUTPATIENTS WITH ATHEROTHROMBOTIC DISEASE
  66. MEDICALLY MANAGED PATIENTS WITH NON ST SEGMENT ACUTE CORONARY SYNDROMES HAVE HETEROGENOUS OUTCOMES, BASED ON PERFORMANCE OF ANGIOGRAPHY, EXTENT OF ANGIOGRAPHIC DISEASE AND AGE
  67. Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume
  68. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors
  69. APIXABAN REDUCES HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION: AN ANALYSIS OF THE EFFECT OF APIXABAN THERAPY ON RESOURCE USE IN THE APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION TRIAL
  70. Impact of Loneliness and Living Alone—Reply
  71. β-Blocker Use for Patients With or at Risk for Coronary Artery Disease—Reply
  72. 262: Use of allopurinol and risk of myocardial infarction: A case-control study
  73. 016: Evidence of systemic plaque vulnerability in acute coronary syndromes with FDG-positron emission tomography and computed tomographic angiography in the BIOCORE-2 study
  74. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation
  75. Registry to provide contemporary information regarding characteristics, management and outcomes of outpatients with stable coronary artery disease
  76. Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syn...
  77. Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation
  78. β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease
  79. Does lay media ranking of hospitals reflect lower mortality in treating acute myocardial infarction?
  80. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial
  81. TCT-742 Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From PROTECT
  82. Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery
  83. Demographics, Socio-Economic Characteristics, and Risk Factor Prevalence in Patients with Non-Cardioembolic Ischaemic Stroke in Low- and Middle-Income Countries: The OPTIC Registry
  84. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
  85. Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study
  86. Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis
  87. Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
  88. An International Model to Predict Recurrent Cardiovascular Disease
  89. Atherothrombotic Disease, Traditional Risk Factors, and 4‐Year Mortality in a Latin American Population: The REACH Registry
  90. Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease
  91. Management and outcomes following an acute coronary event in patients with chronic heart failure 1999–2007
  92. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
  93. Fate of individuals with ischemic amputations in the REACH Registry: Three-year cardiovascular and limb-related outcomes
  94. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort
  95. Recurrent acute coronary syndromes are associated with increased shear induced platelet aggregation. A case–control study
  96. LONG-TERM RISK AND PROGNOSIS OF RECURRENT CARDIOVASCULAR EVENTS IN THE REACH REGISTRY
  97. GREATER EFFICACY OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME IS NOT DRIVEN BY OUTCOMES IN POOR METABOLIZERS OF CLOPIDOGREL
  98. CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS
  99. METABOLIC SYNDROME, DIABETES MELLITUS, OR BOTH AND CARDIOVASCULAR RISK IN OUTPATIENTS AT RISK OF OR WITH ATHEROTHROMBOSIS IN THE REACH REGISTRY
  100. RESISTANT HYPERTENSION: A FREQUENT AND OMINOUS FINDING AMONG HYPERTENSIVE PATIENTS WITH ATHEROTHROMBOSIS
  101. GENDER DIFFERENCES IN CARDIOVASCULAR RISK IN DIABETIC AND NON-DIABETIC OUTPATIENTS AT RISK OF OR WITH ATHEROTHROMBOSIS IN THE REACH REGISTRY
  102. Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: Analysis of the Occluded Artery Trial (OAT)
  103. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis
  104. Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: Implications on optimisation of timing of treatment from the CARESS-in-AMI trial
  105. Editorial
  106. Editorial
  107. Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry)
  108. 023 HIV-infected status is associated with increased recurrence of acute coronary syndrome. Results of long term follow up of the PACS-HIV study
  109. 225 Symptoms, functional status, and quality of life in patients with controlled and uncontrolled atrial fibrillation. Data from the cross-sectional REALISE-AF registry
  110. The Association Between Prior Use of Aspirin and/or Warfarin and the In-hospital Management and Outcomes in Patients Presenting With Acute Coronary Syndromes: Insights From the Global Registry of Acute Coronary Events (GRACE)
  111. Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)
  112. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
  113. Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes
  114. Ethnic Differences in Cardiovascular Risks and Mortality in Atherothrombotic Disease: Insights From the REduction of Atherothrombosis for Continued Health (REACH) Registry
  115. Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry
  116. Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome
  117. Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention
  118. Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  119. A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis
  120. Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes
  121. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial
  122. Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non–ST-elevation acute coronary syndromes
  123. Delphi-Consensus Weights for Ischemic and Bleeding Events to Be Included in a Composite Outcome for RCTs in Thrombosis Prevention
  124. REAL LIFE USE OF ANTITHROMBOTIC TREATMENT IN ATRIAL FIBRILLATION: INSIGHTS FROM THE INTERNATIONAL REALISEAF REGISTRY
  125. ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL
  126. CYSTATIN C IS AN INDEPENDENT RISK PREDICTOR FOR DEATH OR MYOCARDIAL INFARCTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) AS WELL AS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS)
  127. EVALUATION OF THE EFFICACY AND SAFETY OF OTAMIXABAN VS. UNFRACTIONATED HEPARIN+EPTIFIBATIDE IN ELDERLY PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN THE SEPIA-ACS1 TIMI 42 TRIAL
  128. RELATIONSHIP BETWEEN BLEEDING AND MORTALITY IN PATIENTS ON DUAL ANTIPLATELET THERAPY VS ASPIRIN ALONE: RESULTS FROM THE CHARISMA TRIAL
  129. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial
  130. Outcomes from patients with multi‐vessel disease following primary PCI
  131. Safety of Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction (from the BEAUTIFUL Holter Substudy)
  132. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-...
  133. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST
  134. Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention
  135. Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes
  136. Myocardial infarction after blunt chest trauma: usefulness of cardiac ECG-gated CT and MRI for positive and aetiologic diagnosis
  137. Editorial
  138. Editorial
  139. 126 Speckle tracking echocardiography as a potential diagnostic method for acute myocarditis: A pilot comparaison to cardiac MRI
  140. Results from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
  141. Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry
  142. 229 Screening for abdominal aortic aneurysm among patients admitted for acute myocardial infarction using portable transthoracic echocardiography
  143. 012 Acute coronary syndrome in HIV-infected patients: characteristics and prognosis
  144. 240 Pre-hospital abciximab initiation in STEMI. MISTRAL: a prospective controlled randomized double blinded trial
  145. Cardiovascular risk profiles and outcomes of Chinese living inside and outside China
  146. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non–ST-segment elevation...
  147. Can an elderly woman's heart be too strong?
  148. Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events
  149. Recurrent ischemia across the spectrum of acute coronary syndromes: Prevalence and prognostic significance of (Re-)infarction and ST-segment changes in a large contemporary registry
  150. PCV121 A SURVEY OF PHYSICIANS' ATTITUDES TOWARD THE CONTROL OF CARDIOVASCULAR RISK FACTORS. THE EURIKA STUDY.
  151. PCV30 PREVALENCE AND CONTROL OF TRADITIONAL CARDIOVASCULAR RISK FACTORS AND ANTICIPATED AVOIDABLE CORONARY MORTALITY IN PRIMARY PREVENTION IN EUROPE:THE EURIKA STUDY
  152. CV1 USING REAL WORLD DATA TO CALCULATE THE COST-EFFECTIVENESS OF STATIN AMONG PARTICIPNATS WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIAN GENERAL PRACTICE
  153. Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
  154. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis
  155. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry
  156. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
  157. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease
  158. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
  159. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
  160. Prior Cardiovascular Interventions Are Not Associated With Worsened Clinical Outcomes in Patients With Symptomatic Atherothrombosis
  161. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
  162. Assessment of Atherothrombosis and Its Treatment in Mexico: First‐Year Data of the REACH Registry
  163. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA)
  164. Adjunctive Pharmacologic Therapies
  165. Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. The Alliance project
  166. Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease
  167. INTERACTION BETWEEN TIME TO TREATMENT AND TYPE OF REPERFUSION THERAPY IN STEMI: A POOLED ANALYSIS OF ONE-YEAR MORTALITY IN THE COMPARISON OF ANGIOPLASTY & PREHOSPITAL THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION (CAPTIM) AND WHICH EARLY ST-ELEVATION...
  168. Ethnic differences in the relationships of anthropometric measures to metabolic risk factors in Asian patients at risk of atherothrombosis
  169. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
  170. THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL
  171. TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY
  172. Statins in the elderly: What evidence of their benefit in prevention?
  173. Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
  174. Editorial
  175. Editorial
  176. The economic implications of treating atherothrombotic disease in australia, from the government perspective
  177. 014 Risk score to predict serious bleeding in stable outpatients with atherothrombosis
  178. Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial
  179. 008 Circulating secreted phospholipase A2 activity: an early prognostic marker in unselected patients presenting to the emergency department with suspected acute coronary syndrome
  180. 015 The CHADS2 score predicts more accurately adverse cardiovascular outcome in atherothrombotic patients without atrial fibrillation than established scores: Insights from the European REACH registry
  181. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
  182. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: Results from 1-year outcomes in the Japanese REACH Registry
  183. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
  184. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience
  185. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group
  186. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent imp...
  187. Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT)
  188. Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention
  189. Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies
  190. Impact of Systemic Hypertension on the Diagnostic Performance of B-Type Natriuretic Peptide in Patients With Acute Dyspnea
  191. The authors' reply:
  192. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
  193. Immediate vs Delayed Intervention for Acute Coronary Syndromes
  194. Antithrombotics in Acute Coronary Syndromes
  195. Regional and Practice Variation in Adherence to Guideline Recommendations for Secondary and Primary Prevention Among Outpatients With Atherothrombosis or Risk Factors in the United States
  196. Drug Treatment and Cost of Cardiovascular Disease in Australia
  197. The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention
  198. Renal function, atherothrombosis extent, and outcomes in high-risk patients
  199. Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines
  200. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial
  201. Introducción
  202. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry
  203. Validity of a risk-prediction tool for hospital mortality: The Global Registry of Acute Coronary Events
  204. Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States
  205. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes
  206. Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention
  207. T1970 Risk Factors for Digestive Complications in Cardiology Outpatients Treated Chronically with Antiplatelet Agents
  208. Retinal microvascularisation abnormalities and cardiovascular risk
  209. Response to “Atrial fibrillation and atherothrombosis: The importance of anticoagulation” by Escobar C and Barrios V
  210. Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial
  211. Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] ...
  212. Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention
  213. Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?
  214. Universal reperfusion therapy can be implemented: Lessons from 20 years of management of patients admitted within 6 hours of symptom onset with ST-segment elevation acute myocardial infarction
  215. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
  216. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction
  217. Prehospital Delay in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events [GRACE])
  218. ESC Guidelines on Management of Acute Myocardial Infarction in Patients Presenting With Persistent ST-Segment Elevation
  219. Risk Stratification in Non-ST-segment Elevation Acute Coronary Syndromes: Troponin Alone Is not Enough
  220. Acute coronary angiographic findings in survivors of out-of-hospital cardiac arrest
  221. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
  222. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: Results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial
  223. Thrombocytopenia in Patients With an Acute Coronary Syndrome (from the Global Registry of Acute Coronary Events [GRACE])
  224. Ivabradine in heart failure: what about digoxin? – Authors' reply
  225. A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE)
  226. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis
  227. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: Data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
  228. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
  229. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
  230. A Meta-Analysis That Misses the Mark
  231. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry
  232. CARESS-in-AMI study – Authors' reply
  233. Does PERISCOPE Provide a New Perspective on Diabetic Treatment?
  234. Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice
  235. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial
  236. Reply
  237. Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry
  238. The paradox of cholesterol and stroke
  239. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects
  240. Revascularization Before Noncardiac Surgery: Is There an Impact of Drug-Eluting Stent Thrombosis?
  241. Resting Heart Rate in Cardiovascular Disease
  242. Prothrombotic markers and early spontaneous recanalization in st-segment elevation myocardial infarction
  243. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non–ST elevation acute coronary syndromes
  244. Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events)
  245. Measurement and prevention of myocardial injury during percutaneous coronary intervention
  246. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006
  247. Clinical End Points in Coronary Stent Trials
  248. Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry)
  249. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial
  250. Does Preventive PCI Work?
  251. Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification
  252. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis
  253. A Cause for Concern
  254. Do the benefits of early invasive therapy for non-STE acute coronary syndromes persist with long-term follow-up?
  255. External Validity of Clinical Trials in Acute Myocardial Infarction
  256. Use of Heparins in Non-ST-Elevation Acute Coronary Syndromes
  257. Prevalence, Awareness and Treatment of Cardiovascular Risk Factors in Patients at High Risk of Atherothrombosis in Japan
  258. Coronary Intervention for Persistent Occlusion after Myocardial Infarction
  259. Ischemia-Modified Albumin in Acute Stroke
  260. Patterns of use and potential impact of early β-blocker therapy in non–ST-elevation myocardial infarction with and without heart failure: The Global Registry of Acute Coronary Events
  261. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in p...
  262. Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention
  263. A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
  264. Predischarge C-Reactive Protein and 1-year Outcome After Acute Coronary Syndromes
  265. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
  266. Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction
  267. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
  268. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE)
  269. Reply
  270. Impact of the History of Congestive Heart Failure on the Utility of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure: Results from the Breathing Not Properly Multinational Study
  271. Is Primary Angioplasty More Effective Than Prehospital Fibrinolysis in Diabetics With Acute Myocardial Infarction? Data From the CAPTIM Randomized Clinical Trial
  272. Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes
  273. Unmet medical needs and therapeutic opportunities in stable angina
  274. A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  275. Medication performance measures and mortality following acute coronary syndromes
  276. B-Type Natriuretic Peptide and Echocardiographic Determination of Ejection Fraction in the Diagnosis of Congestive Heart Failure in Patients With Acute Dyspnea
  277. Enhanced Shear-Induced Platelet Aggregation in Patients Who Experience Subacute Stent Thrombosis
  278. Cigarette smoking and acute coronary syndromes: A multinational observational study
  279. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting
  280. Atherothrombosis and Stroke – A Lot More to Know!
  281. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study)
  282. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)
  283. Impact of the history of congestive heart failure on accuracy of BNP in the emergency diagnosis of heart failure: results from the breathing not properly (BNP) multinational study
  284. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study
  285. A Validated Prediction Model for All Forms of Acute Coronary Syndrome
  286. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study
  287. La définition de la resténose vue par le clinicien : aspects méthodologiques et angiographiques
  288. 815-4 Impact of an open artery late after infarction: Angiographic results of the DECOPI randomized trial
  289. 859-2 Utility of B-natriuretic peptide levels in predicting outcome of hospitalized patients with congestive heart failure: Results of the breathing not properly (BNP) multinational study
  290. Syndromes coronariens aigus : un changement de paradigme
  291. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE])
  292. Circadian variations in outcome ofprimary percutaneous coronary intervention
  293. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
  294. The impact of age, race and gender on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the breathing not properly (BNP) multinational study
  295. Patterns of use of heparins in ACS
  296. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction
  297. Determinants of use and outcomes of invasive coronary procedures in acute coronary syndromes: results from ENACT
  298. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non–ST-segment elevation acute myocardial infarction (the ARMADA study)
  299. A comparison of bedside B-type natriuretic peptide versus echocardiographic determination of ejection fraction in the diagnosis of heart failure
  300. Uncovering heart failure in patients with bronchospasm: Rationale for the early use of B-type natriuretic peptide in the emergency department
  301. What is in the differential diagnosis of a B-type natriuretic peptide level of 1,000 pg/ml?
  302. What causes elevated B-type natriuretic peptide in patients without heart failure?
  303. Acute coronary syndrome patients with ST-segment depression have substantial mortality rates but undergo less aggressive management strategies: Insights from the global registry of acute coronary events (GRACE)
  304. A robust prediction model for all forms of acute coronary syndromes: Estimating the risk of in-hospital death and myocardial infarction in the global registry of acute coronary events registry
  305. Beside B-type natriuretic peptide in the emergency diagnosis of systolic and nonsystolic heart failure: Results from the breathing not properly (BNP) multinational study
  306. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the BNP multinational study
  307. Stable Angina
  308. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab
  309. Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction
  310. Low–molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus*
  311. Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) study
  312. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study
  313. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list o...
  314. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry)
  315. Determinants and outcomes of congestive heart failure complicating acute coronary syndromes: observations from the global registry of acute coronary events
  316. Improved outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery treated with combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition
  317. The independent contribution to elevations in B-type natriuretic peptide from atrial fibrillation
  318. B-type natriuretic peptide in the emergency diagnosis of diastolic dysfunction heart failure
  319. The effect of diabetes on B-type natriuretic peptide levels in patients with acute dyspnea
  320. B-type natriuretic peptide adds to clinical judgement in the diagnosis of heart failure: a bayesian analysis from the BNP multinational study
  321. Primary results of the BNP multinational study: B-type natriuretic peptide in the emergency diagnosis of heart failure
  322. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms
  323. Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris
  324. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction
  325. Chronic radiodermatitis after cardiac catheterization
  326. Myocardial infarction after aspirin cessation in stable coronary artery disease patients
  327. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction
  328. Reperfusion syndrome: relationship of coronary blood flow reserve to left ventricular function and infarct size
  329. Aspirine et prévention du risque cardiovasculaire
  330. Nouvelles approches en cardiologie interventionnelle.
  331. Catheter-based reperfusion of unprotected left main stenosis during an acute myocardial infarction (the ULTIMA experience)
  332. Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina
  333. NC100100, a new echo contrast agent for the assessment of myocardial perfusion—safety and comparison with technetium‐99m sestamibi single‐photon emission computed tomography in a randomized multicenter study
  334. Rest reverse redistribution in acute reperfused myocardial infarction: Significance of post-injection Tl-SPECT images
  335. Comparison of the prognostic value of C-Reactive protein and troponin I in patients with unstable angina pectoris
  336. Incidence, consequences, and risk factors of early reocclusion after primary and/or rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction
  337. Hospital outcome after bailout coronary stenting in patients with acute myocardial infarction
  338. A critical analysis of the concept of silent myocardial ischaemia
  339. S31 The clinical promise of clopidogrel
  340. Arterial response to mild balloon injury in the normal rabbit
  341. Revascularization of Patients With Unstable Coronary Artery Disease
  342. Conservative management of patients with acute myocardial infarction and spontaneous acute patency of the infarct-related artery
  343. Are the Results of Primary Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial Infarction Different During the “Off” Hours?
  344. Myocardial contrast echocardiography to assess spontaneous reperfusion during myocardial infarction
  345. Radial access for primary PTCA in patients with acute myocardial infarction and contraindication to or impossible femoral access
  346. Decreased prevalence of late potentials with mechanical versus thrombolysis-induced reperfusion in acute myocardial infarction
  347. Perspectives de thérapie génique de la resténose
  348. Nonlimited exercise test combined with high-dose dipyridamole for thallium-201 myocardial single-photon emission computed tomography in coronary artery disease
  349. Comparison using dynamic vectorcardiography and MIBI SPECT of ST-segment changes and myocardial MIBI uptake during percutaneous transluminal coronary angioplasty of the left anterior descending coronary artery
  350. 901-18 Naroparcil, a β-D Xyloside Analog, Limits Intimal Hyperplasia After Arterial Injury
  351. 957-108 Does Reperfusion Induced by Angioplasty Confer the Same Benefit as Thrombolysis in Terms of Late Potentials?
  352. Prevention of restenosis after coronary angioplasty: towards a molecular approach?
  353. Modulation of the Expression of the Granulocyte Adhesion Molecule, CR3, by Percutaneous Transluminal Coronary Angioplasty and Contrast Media
  354. Late thrombotic obstruction of an aortic bioprosthetic valve: Successful treatment by oral anticoagulation
  355. Utilization of Laser Arterial Angioplasty
  356. Acute Left Ventricular Dysfunction during Unsuccessful Weaning from Mechanical Ventilation
  357. Percutaneous, in vivo excimer laser angioplasty: Results in two experimental animal models
  358. Arterial Gene Transfer